Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06475053 · ClinicalTrials.gov registry record · NA
Visual Performance of Center Distance Daily Disposable Multifocal Lenses
A NA study of Myopia, sponsored by Visioneering Technologies.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06475053: Active NA study of Myopia, sponsored by Visioneering Technologies.
NCT06475053 is a NA study of Myopia that is active but no longer recruiting, run by Visioneering Technologies. The registered enrollment target is 30 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06475053, a NA study of Myopia, is active but no longer recruiting, sponsored by Visioneering Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare visual performance (high and low contrast acuity, reading acuity, contrast sensitivity, stereoacuity, accommodative response, eye hand coordination, far near vision, and dynamic vision) between Visioneering Technologies, Inc. NaturalVue Multifocal and CooperVivion MiSight.
Primary Outcome
log MAR vision scale
Conditions Studied
Interventions
- DEVICE NaturalVue Enhanced Multifocal 1 Day contact lens
- DEVICE MiSight 1 Day contact lens
Study Locations (1)
Ohio
- The Ohio State University College of Optometry - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the registry record for NCT06475053 still lists
NCT06475053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which NaturalVue Enhanced Multifocal 1 Day contact lens is the first listed.
NCT06475053 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06475053 about?
NCT06475053 is a clinical study titled "Visual Performance of Center Distance Daily Disposable Multifocal Lenses". The purpose of this study is to compare visual performance (high and low contrast acuity, reading acuity, contrast sensitivity, stereoacuity, accommodative response, eye hand coordination, far near vision, and dynamic vision) between Visioneering Technologies, Inc. NaturalVue Multifocal and CooperVi...
What is the current status of trial NCT06475053?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-07-31. Estimated completion is 2025-12-31.
What conditions does trial NCT06475053 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT06475053?
The interventions under investigation include: NaturalVue Enhanced Multifocal 1 Day contact lens (DEVICE), MiSight 1 Day contact lens (DEVICE).
Who is sponsoring clinical trial NCT06475053?
This trial is sponsored by Visioneering Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06475053 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06475053's enrollment target sits among peer trials
30 86th of 90 higher than 4 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI